A phase III comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus docetaxel in patients with previously treated advanced or metastatic squamous cell non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Borghaei, Hossein
Lynch, Thomas James
Rizvi, Naiyer A.
Chow, Laura Quan Man
Reilly, Robert
Crino, Lucio
Buyse, Marc E.
Ezzeddine, Rana
Lestini, Brian Joseph
Brahmer, Julie R.
机构：
[1] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[2] Yale Univ, Sch Med, New Haven, CT USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[4] Univ Washington, Seattle, WA 98195 USA
[5] St Mary Hosp, Langhorne, PA USA
[6] Azienda Osped Perugia, Perugia, Italy
[7] Int Inst Drug Dev, Louvain, Belgium
[8] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[9] Bristol Myers Squibb Co, Princeton, NJ USA
[10] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8122
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM).
    Sampson, John Howard
    Viahovic, Gordana
    Desjardins, Annick
    Friedman, Henry S.
    Baehring, Joachim M.
    Hafler, David
    Rollin, Linda
    Coric, Viad
    Perez, Susan N.
    Reardon, David A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [42] Phase I/II, open-label study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) as monotherapy or combined with ipilimumab in advanced or metastatic solid tumors.
    Callahan, Margaret K.
    Bendell, Johanna C.
    Chan, Emily
    Morse, Michael
    Pillai, Rathi Narayana
    Bono, Petri
    Jaeger, Dirk
    Evans, T. R. Jeffry
    Chau, Ian
    Calvo, Emillano
    Le, Dung T.
    Ott, Patrick Alexander
    Taylor, Matthew Hiram
    Sharma, Padmanoo
    Antonia, Scott Joseph
    Sharkey, Brian
    Christensen, Olaf
    Amin, Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [43] CLINICAL ACTIVITY AND SAFETY OF ANTI-PROGRAMMED DEATH-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) IN PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Gettinger, S.
    Horn, L.
    Antonia, S. J.
    Spigel, D.
    Gandhi, L.
    Sequist, L. V.
    Wigginton, J. M.
    Kollia, G.
    Gupta, A.
    Brahmer, J. R.
    ANNALS OF ONCOLOGY, 2012, 23 : 405 - 406
  • [44] Phase I dose escalation study of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis
    Sangro, Bruno
    Crocenzi, Todd S.
    Welling, Theodore Hobart
    Inarrairaegui, Mercedes
    Prieto, Jesus
    Fuertes, Carmen
    Delanty, Laurie
    Feely, William
    Anderson, Jeffrey
    Grasela, Dennis M.
    Wigginton, Jon M.
    Gupta, Ashok Kumar
    Melero, Ignacio
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [45] PHASE I STUDY OF ANTI-PD-1 ANTIBODY ONO-4538 AND CHEMOTHERAPY IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER
    Kanda, Shintaro
    Tanaka, Ayako
    Utsumi, Hirofumi
    Sunami, Kuniko
    Mizugaki, Hidenori
    Horinouchi, Hidehito
    Fujiwara, Yutaka
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Tamura, Tomohide
    ANNALS OF ONCOLOGY, 2014, 25
  • [46] Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538).
    Grosso, Joseph
    Horak, Christine E.
    Inzunza, David
    Cardona, Diana M.
    Simon, Jason S.
    Gupta, Ashok Kumar
    Sankar, Vindira
    Park, Jong-Soon
    Kollia, Georgia
    Taube, Janis M.
    Anders, Robert
    Jure-Kunkel, Maria
    Novotny, Jim, Jr.
    Taylor, Clive R.
    Zhang, Xiaoling
    Phillips, Therese
    Simmons, Pauline
    Cogswell, John
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [47] Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies
    Sznol, M.
    Powderly, J. D.
    Smith, D. C.
    Brahmer, J. R.
    Drake, C. G.
    McDermott, D. F.
    Lawrence, D. P.
    Wolchok, J. D.
    Topalian, S. L.
    Lowy, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [48] First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status.
    Gettinger, Scott N.
    Shepherd, Frances A.
    Antonia, Scott Joseph
    Brahmer, Julie R.
    Chow, Laura Quan Man
    Juergens, Rosalyn A.
    Borghaei, Hossein
    Shen, Yun
    Harbison, Christopher
    Alaparthy, Suresh
    Chen, Allen C.
    Rizvi, Naiyer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [49] A phase III, randomized, open-label trial of nivolumab (anti-PD-1) ; BMS-936558, ONO-4538) versus investigator's choice chemotherapy (ICC) as first-line therapy for stage IV or recurrent PD-L1+non-small cell lung cancer (NSCLC)
    Carbone, David Paul
    Socinski, Mark A.
    Chen, Allen C.
    Bhagavatheeswaran, Prabhu
    Reck, Marlin
    Paz-Ares, Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [50] Phase II Study of Nivolumab (ONO-4538/BMS-936558) for Esophageal Cancer: Clinical activity by PD-L1 expression analysis
    Hara, Hiroki
    Kojima, Takashi
    Hironaka, Shuichi
    Kato, Ken
    Tsushima, Takahiro
    Ura, Takashi
    Doki, Yuichiro
    Ohtsu, Atsushi
    Hamamoto, Yasuo
    Kitagawa, Yuko
    ANNALS OF ONCOLOGY, 2016, 27
12345